US Stock MarketDetailed Quotes

ACRS Aclaris Therapeutics

Watchlist
  • 2.720
  • -0.050-1.81%
Close Dec 20 16:00 ET
  • 3.000
  • +0.280+10.29%
Post 20:01 ET
291.00MMarket Cap-5.23P/E (TTM)

About Aclaris Therapeutics Company

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Company Profile

SymbolACRS
Company NameAclaris Therapeutics
Listing DateOct 7, 2015
Issue Price11.00
Founded2012
CEODr. Neal Walker, D.O.
MarketNASDAQ
Employees91
Fiscal Year Ends12-31
Address701 Lee Road,Suite 103
CityWayne
ProvincePennsylvania
CountryUnited States of America
Zip Code19087
Phone1-484-324-7933

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Neal Walker, D.O.
  • Chairman of the Board and Interim Chief Executive Officer
  • 73.50K
  • James Loerop
  • Chief Business Officer
  • 2.33M
  • Kevin Balthaser
  • Chief Financial Officer and Principal Accounting Officer
  • 2.34M
  • Dr. Joseph Monahan, PhD
  • Chief Scientific Officer
  • 2.26M
  • Dr. Hugh Davis, PhD
  • President, Chief Operating Officer and Director
  • --
  • Dr. Maxine Gowen,PhD
  • Independent Director
  • 206.38K
  • Vincent J. Milano
  • Independent Director
  • 180.38K
  • Dr. Andrew N. Schiff, M.D.
  • Independent Director
  • 186.38K
  • William D. Humphries
  • Independent Director
  • 177.38K
  • Christopher Molineaux
  • Lead Independent Director
  • 206.88K
  • Dr. Anand Mehra, M.D.
  • Independent Director
  • 194.38K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.